Saint Prex, 3rd December 2008 - BioGaia has extended its collaboration with the Swiss biopharmaceutical company Ferring Pharmaceuticals giving Ferring exclusive rights to sell BioGaia's Probiotic Drops in Ireland and exclusive rights to sell BioGaia's Probiotic Drops and Tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and United Arab Emirates.
"We are very happy to again expand the contract with Ferring in to these interesting markets. Ferring is taking the BioGaia brand to markets we have not been before and it is yet another step in our effort to build a global probiotic brand ", says Peter Rothschild, President, BioGaia AB.
"Our collaboration with BioGaia is going very well. BioGaia's Probiotic therapeutic products have been very well received by the medical profession and patients in the countries where we have already launched and we are very happy to be able to make it available to patients in the Gulf States and Ireland," says Michel Pettigrew, COO at Ferring
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.
Ferring Pharmaceuticals is a Swiss-based research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and has operations in over 40 countries. To learn more about Ferring or its products please visit www.ferring.com.
Tel: +41 58 301 00 51, Fax: +41 58 301 0039
telephone: +46 8 - 555 293 00,
Deputy Managing Director,
telephone: +46 8 - 555 293 00